India's pharmaceutical exports grew 9.7% in 2025 to $30.45 billion, despite the Sigachi industrial accident, with the government ensuring quality through regulatory measures.
The government ensures drug quality through the Central Drugs Standard Control Organization and state licensing authorities, and engages in bilateral trade talks to prevent non-tariff barriers.
Safety protocols and inspections are emphasized following the Sigachi accident, with training and inspections to ensure compliance with the Occupational Safety, Health and Working Conditions Code, 2020.